#StopFakeMeds #ThinkSmart
American choices in pharmaceutical production are reshaping the global landscape. The transition ahead opens a breach: one that fake medicines and medical devices are ready to exploit, to the detriment of all.
Since August 2025, Washington has imposed a 15% tariff on finished European medicines and 10% on Indian ones. Starting in September, European and Indian generics will be exempted under the WTO’s Most Favoured Nation principle (MFN). In contrast, Active Pharmaceutical Ingredients (APIs) and branded medicines remain taxed, and medical devices, already heavily surcharged, continue to face high tariffs. At the same time, US Sections 301 and 232 continue to enforce additional tariffs of 25–50% against China and other countries.
Under pressure, major pharmaceutical companies are seeking to protect their shares in the American market – the most profitable – by announcing massive investments and new pricing strategies (direct-to-patient sales, hybrid models). The result: a brutal reorientation of global supply flows. Yet these strategic moves, many slow to implement, neglect urgent security priorities: temporary diversification of sources, reinforced border controls, public information, and international cooperation.
Domino effect: generic flows will shift towards the United States, draining Europe, Africa, and Latin America. Despite the 15% tariff on other products, European companies, constrained by price regulations at home, will maintain their prices and prioritize the U.S. market – freer, larger, and far more profitable, where medicines sell for 5 to 10 times more.
Key point: more than 80% of APIs come from China and India. This is the legacy of industrial offshoring initiated in the 1970s to cut production costs. As long as this structural dependency persists, no country – not even the United States – is safe. The absorption of flows and the relocation of production to the U.S. only reinforce the need to diversify sources.
Europe is attempting to anticipate by focusing on securing its internal market. The Internal Market Emergency and Resilience Act (IMERA – July 2025) creates a crisis-management framework, but APIs are not yet covered. Strategic stockpiles, expanded to include antibiotics and cancer medicines, remain insufficient. The FMD traceability system, too rigid, risks blocking legitimate shipments or, in emergencies, letting suspicious ones through. Projects to build plants in Eastern Europe and Africa, or technology transfers to Latin America, will only bear fruit in the long term. These regions may become the most exposed: chronic shortages, rushed bilateral agreements, imports of second-line generics, with resulting quality risks and the rise of parallel markets where substandard and fake medicines intermingle.
The pharmaceutical diversification that is emerging is neither ethical nor cooperative. It is defensive, reactive, and driven by cost logic.
One certainty remains: our vigilance!
– Buy only through official channels
– Refuse dubious online offers
– Report any suspicious case
